Monoacylglycerol lipase - A target for drug development?

British Journal of Pharmacology

Volumn 166, Issue 5, 2012, Pages 1568-1585

  Fowler, C J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

2 arachidonoylglycerol; anandamide; cancer; cannabinoid; fatty acid amide hydrolase; monoacylglycerol lipase; pain

Indexed keywords

1,6 HEXAMETHYLENEDICARBAMIC ACID BIS(CYCLOHEXANONE OXIME) ESTER; ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; ENDOCANNABINOID; ESTERASE INHIBITOR; JZL 184; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONOYL AMIDE; OMDM 169; UNCLASSIFIED DRUG; URB 602;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANTINEOPLASTIC ACTIVITY; APPETITE; CANCER INHIBITION; CANCER INVASION; CANCER PAIN; COLITIS; COLORECTAL CANCER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE DELETION; GENE SILENCING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OVARY CANCER; PAIN; PATHOPHYSIOLOGY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; TRANQUILIZING ACTIVITY;

ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MONOACYLGLYCEROL LIPASES; NEOPLASMS; PAIN;

EID: 84862742406     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01950.x     Document Type: Review

References (156)

1. Ahn K, Johnson DS, Cravatt BF, (2009). Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders Expert Opin Drug Discov 4: 763-784.
2. Alger BE, Kim J, (2011). Supply and demand for endocannabinoids. Trends Neurosci 34: 304-315.
3. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG, (2011). Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 25: 2711-2721.
4. Alkaitis MS, Solorzano C, Landry RP, Piomelli D, DeLeo JA, Romero-Sandoval EA, (2010). Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of postoperative pain. PLoS ONE 5: e10891.
5. 2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160: 467-479.
6. Bab I, Zimmer A, (2008). Canabinoid receptors and the regulation of bone mass. Br J Pharmacol 153: 182-188.
7. Bambico FR, Cassano T, Dominguez-Lopez S, Katz N, Walker CD, Piomelli D, et al,. (2010). Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus. Neuropsychopharmacology 35: 2083-2100.
8. Basu S, Dittel BN, (2011). Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 51: 26-38.
9. Beaulieu P, (2006). Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 53: 769-775.
10. Beaulieu P, Ware M, (2007). Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 20: 473-477.
11. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee M-H, Vogel Z, et al,. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353: 23-31.
12. Bertrand T, Augé F, Houtmann J, Rak A, Vallée F, Mikol V, et al,. (2010). Structural basis for human monoglyceride lipase inhibition. J Mol Biol 396: 663-673.
13. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Marzo V, (2004). A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606-1608.
14. Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, et al,. (2009). Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim Biophys Acta 1791: 53-60.
15. Björklund E, Noren E, Nilsson J, Fowler CJ, (2010). Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays. Br J Pharmacol 161: 1512-1526.
16. 1 receptors in Achilles tendinosis. PLoS ONE 6: e24731.
17. Blankman JL, Simon GM, Cravatt BF, (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14: 1347-1356.
18. Burston J, Sim-Selley L, Harloe J, Mahadevan A, Razdan R, Selley D, et al,. (2008). N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J Pharmacol Exp Ther 327: 546-553.
19. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A, (2011). Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70: 479-486.
20. Campbell F, Tramèr M, Carroll D, Reynolds J, Moore R, McQuay H, (2001). Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J 323: 13-16.
21. Chanda PK, Gao Y, Mark L, Btesh J, Strassle BW, Lu P, et al,. (2010). Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 78: 996-1003.
22. Chevaleyre V, Castillo PE, (2003). Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38: 461-472.
23. 1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 45: 174-182.
24. Cisneros JA, Vandevoorde S, Ortega-Gutierrez S, Paris C, Fowler CJ, Lopez-Rodriguez ML, (2007). Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis-comparison with effects upon fatty acid amide hydrolase. J Med Chem 50: 5012-5023.
25. Cisneros JA, Björklund E, Gonzalez-Gil I, Hu Y, Canales A, Medrano FJ, et al,. (2012). Structure-activity relationship of a new series of reversible dual monoacylglycerol lipase/fatty Acid amide hydrolase inhibitors. J Med Chem 55: 824-836.
26. 2 receptors determines their efficacy at inducing apoptosis in astrocytomas. PLoS ONE 5: e8702.
27. De Petrocellis L, Di Marzo V, (2009). An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 23: 1-15.
28. Desroches J, Guindon J, Lambert C, Beaulieu P, (2008). Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 155: 913-924.
29. Devane W, Hanus L, Breuer A, Pertwee R, Stevenson L, Griffin G, et al,. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
30. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner J, et al,. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264: 258-267.
31. Díaz-Laviada I, (2011). The endocannabinoid system in prostate cancer. Nat Rev Urol 8: 553-561.
32. Dinh T, Carpenter D, Leslie F, Freund T, Katona I, Sensi S, et al,. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 10819-10824.
33. Duggan KC, Hermanson DJ, Musee J, Prusakiewicz JJ, Scheib JL, Carter BD, et al,. (2011). (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol 7: 803-809.
34. Duncan M, Thomas A, Cluny N, Patel A, Patel K, Lutz B, et al,. (2008). Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 295: G1255-G1265.
35. Fan S-F, Yazulla S, (2007). Retrograde endocannabinoid inhibition of goldfish retinal cones is mediated by 2-arachidonoyl glycerol. Vis Neurosci 24: 257-267.
36. Flygare J, Sander B, (2008). The endocannabinoid system in cancer-potential therapeutic target? Semin Cancer Biol 18: 176-189.
37. 1 receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer. PLoS ONE 5: e15205.
38. Fowler CJ, Gustafsson SB, Chung SC, Persson E, Jacobsson SOP, Bergh A, (2010b). Targeting the endocannabinoid system for the treatment of cancer-a practical view. Curr Top Med Chem 10: 814-827.
39. Freimuth N, Ramer R, Hinz B, (2010). Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther 332: 336-344.
40. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, et al,. (2010). Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 30: 2017-2024.
41. Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, Martin BR, et al,. (2004). Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol 143: 774-784.
42. Glaser ST, Kaczocha M, (2010). Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. J Pharmacol Exp Ther 335: 380-388.
43. Goparaju S, Ueda N, Yamaguchi H, Yamamoto S, (1998). Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Letts 422: 69-73.
44. Goparaju S, Ueda N, Taniguchi K, Yamamoto S, (1999). Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57: 417-423.
45. Guindon J, Hohmann AG, (2009). The endocannabinoid system and pain. CNS Neurol Disord Drug Targets 8: 403-421.
46. Guindon J, Guijarro A, Piomelli D, Hohmann AG, (2011). Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 163: 1464-1478.
47. Gulyas A, Cravatt B, Bracey M, Dinh T, Piomelli D, Boscia F, et al,. (2004). Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20: 441-458.
48. Hansen HS, (2010). Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 224: 48-55.
49. Hanus L, Gopher A, Almog S, Mechoulam R, (1993). Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36: 3032-3034.
50. 1 receptor. Proc Natl Acad Sci USA 98: 3662-3665.
51. Hashimotodani Y, Ohno-Shosaku T, Kano M, (2007). Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J Neurosci 27: 1211-1219.
52. Hiley CR, (2009). Endocannabinoids and the heart. J Cardiovasc Pharmacol 53: 267-276.
53. Hohmann A, Suplita R, Bolton N, Neely M, Fegley D, Mangieri R, et al,. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112.
54. 2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFκB activity. Br J Pharmacol 153: 1538-1549.
55. Idris AI, Ralston SH, (2010). Cannabinoids and bone: friend or foe? Calcif Tissue Int 87: 285-297.
56. Jarzimski C, Karst M, Zoerner AA, Rakers C, May M, Suchy MT, et al,. (2012). Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? Br J Clin Pharmacol (in press). doi: 10.1111/j.1365-2125.2012.04175.x.
57. Jhaveri M, Richardson D, Kendall D, Barrett D, Chapman V, (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26: 13318-13327.
58. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT, (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39: 167-179.
59. Justinova Z, Mangieri R, Bortolato M, Chefer S, Mukhin A, Clapper J, et al,. (2008). Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiat 64: 930-937.
60. Karlsson M, Contreras J, Hellman U, Tornqvist H, Holm C, (1997). cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272: 27218-27223.
61. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al,. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
62. Katona I, Freund TF, (2008). Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 14: 923-930.
63. Kehlet H, Jensen TS, Woolf CJ, (2006). Persistent postsurgical pain: risk factors and prevention. Lancet 367: 1618-1625.
64. Keimpema E, Mackie K, Harkany T, (2011). Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci 32: 551-561.
65. Kerbel R, (2003). Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2: S134-S139.
66. Khasabova IA, Chandiramani A, Harding-Rose C, Simone DA, Seybold VS, (2011). Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol Res 64: 60-67.
67. Kim J, Alger B, (2004). Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 7: 697-698.
68. King A, Duranti A, Tontini A, Rivara S, Rosengarth A, Clapper J, et al,. (2007). URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol 14: 1357-1365.
69. King AR, Lodola A, Carmi C, Fu J, Mor M, Piomelli D, (2009a). A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. Br J Pharmacol 157: 974-983.
70. King AR, Dotsey EY, Lodola A, Jung KM, Ghomian A, Qiu Y, et al,. (2009b). Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem Biol 16: 1045-1052.
71. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH, (2010). Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 11: 1420-1428.
72. Kinsey SG, Nomura DK, O'Neal ST, Long JZ, Mahadevan A, Cravatt BF, et al,. (2011a). Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338: 795-802.
73. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH, (2011b). Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98: 21-27.
74. Kitz R, Wilson IB, (1962). Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237: 3245-3249.
75. Kozak K, Crews B, Morrow J, Wang L-H, Ma Y, Weinander R, et al,. (2002a). Metabolism of the endocannabinoids, 2-arachidonoylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44878-44885.
76. Kozak K, Gupta R, Moody J, Ji C, Boeglin W, DuBois R, et al,. (2002b). 15-Lipoxygenase metabolism of 2-arachidonoylglycerol. Generation of a peroxisome proliferator-activated receptor α agonist. J Biol Chem 277: 23278-23286.
77. Kreitzer A, Regehr W, (2001). Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29: 717-727.
78. Labar G, Bauvois C, Muccioli G, Wouters J, Lambert D, (2007). Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. Chembiochem 8: 1293-1297.
79. Labar G, Bauvois C, Borel F, Ferrer J-L, Wouters J, Lambert DM, (2010). Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling. Chembiochem 11: 218-227.
80. Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni O, (2007). Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS ONE 2: e709.
81. 3 adenosine receptor. Biochem Pharmacol 79: 48-56.
82. Long JZ, Nomura DK, Cravatt BF, (2009a). Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
83. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al,. (2009b). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
84. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al,. (2009c). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106: 20270-20275.
85. Long JZ, Jin X, Adibekian A, Li W, Cravatt BF, (2010). Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. J Med Chem 53: 1830-1842.
86. Ludányi A, Hu SS-J, Yamazaki M, Tanimura A, Piomelli D, Watanabe M, et al,. (2011). Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience 174: 50-63.
87. Lynch ME, Campbell F, (2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72: 735-744.
88. Ma W-X, Yu T-S, Fan Y-Y, Zhang S-T, Ren P, Wang S-B, et al,. (2011). Time-dependent expression and distribution of monoacylglycerol lipase during the skin-incised wound healing in mice. Int J Legal Med 125: 549-558.
89. Maccarrone M, (2009). Endocannabinoids: friends and foes of reproduction. Prog Lipid Res 48: 344-354.
90. Magrioti V, Naxakis G, Hadjipavlou-Litina D, Makriyannis A, Kokotos G, (2008). A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity. Bioorg Med Chem Lett 18: 5424-5427.
91. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M, (2008). Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 6: 119-124.
92. Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M, (2011). Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 15: 297-308.
93. 1 antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol Biochem Behav 94: 154-162.
94. Marrs WR, Blankman JL, Horne EA, Thomazeau A, Lin YH, Coy J, et al,. (2010). The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 13: 951-957.
95. Matuszak N, Muccioli GG, Labar G, Lambert DM, (2009). Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem 52: 7410-7420.
96. Matuszak N, Es Saadi B, Labar G, Marchand-Brynaert J, Lambert DM, (2011). Benzisothiazolinone as a useful template for the design of new monoacylglycerol lipase inhibitors: investigation of the target residues and comparison with octhilinone. Bioorg Med Chem Lett 21: 7321-7324.
97. Mechoulam R, (1986). The pharmacohistory of Cannabis sativa. In:, Mechoulam R, (ed.). Cannabis as Therapeutic Agents. CRC Press: Boca Raton, FL, pp. 1-19.
98. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski N, Schatz A, et al,. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
99. Mechoulam R, Fride E, Ben-Shabat S, Meiri U, Horowitz M, (1998). Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol 362: R1-R3.
100. Michalski C, Oti F, Erkan M, Sauliunaite D, Bergmann F, Pacher P, et al,. (2008). Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122: 742-750.
101. Muccioli G, Labar G, Lambert D, (2008). CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay. Chembiochem 9: 2704-2710.
102. Munson A, Harris L, Friedman M, Dewey W, Carchman R, (1975). Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55: 597-602.
103. Naidu P, Booker L, Cravatt B, Lichtman A, (2009). Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 329: 48-56.
104. Nithipatikom K, Endsley M, Isbell M, Falck J, Iwamoto Y, Hillard C, et al,. (2004). 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64: 8826-8830.
105. Nithipatikom K, Endsley M, Isbell M, Wheelock C, Hammock B, Campbell W, (2005). A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332: 1028-1033.
106. Nomura D, Blankman J, Simon G, Fujioka K, Issa R, Ward A, et al,. (2008). Activation of the endocannabinoid system by organophosphorous nerve agents. Nature Chem Biol 4: 373-378.
107. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF, (2010). Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140: 49-61.
108. Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, et al,. (2011a). Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 18: 846-856.
109. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MCG, et al,. (2011b). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
110. Ohno-Shosaku T, Maejima T, Kano M, (2001). Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29: 729-738.
111. Ortar G, Bisogno T, Ligresti A, Morera E, Nalli M, Di Marzo V, (2008). Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem 51: 6970-6979.
112. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, et al,. (2009). Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl) piperidine-1-carboxylate (JZL184) enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 331: 591-597.
113. Pan B, Wang W, Zhong P, Blankman JL, Cravatt BF, Liu Q-S, (2011). Alterations of endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase knock-out mice. J Neurosci 31: 13420-13430.
114. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanuš L, Breuer A, Mechoulam R, et al,. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531.
115. 2. Pharmacol Rev 62: 588-631.
116. Quarta C, Mazza R, Obici S, Pasquali R, Pagotto U, (2011). Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 17: 518-526.
117. Quistad G, Klintenberg R, Caboni P, Liang S, Casida J, (2006). Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice. Toxicol Appl Pharmacol 211: 76-83.
118. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, et al,. (2011). Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339: 173-185.
119. Reynolds J, (1890). On the therapeutical uses and toxic effects of cannabis indica. Lancet 135: 637-638.
120. Rice ASC, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, et al,. (2008). Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 139: 243-247.
121. Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, et al,. (2008). Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10: R43.
122. Saario S, Salo O, Nevalainen T, Poso A, Laitinen J, Järvinen T, et al,. (2005). Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 12: 649-656.
123. Sarfaraz S, Adhami V, Syed D, Afaq F, Mukhtar H, (2008). Cannabinoids for cancer treatment: progress and promise. Cancer Res 68: 239-242.
124. Schelling G, Hauer D, Azad SC, Schmoelz M, Chouker A, Schmidt M, et al,. (2006). Effects of general anesthesia on anandamide blood levels in humans. Anesthesiology 104: 273-277.
125. Schlosburg JE, Carlson BLA, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, et al,. (2009). Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11: 342-352.
126. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al,. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13: 1113-1119.
127. Sciolino NR, Zhou W, Hohmann AG, (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64: 226-234.
128. Shimizu T, Lu L, Yokotani K, (2011). Endogenously generated 2-arachidonoylglycerol plays an inhibitory role in bombesin-induced activation of central adrenomedullary outflow in rats. Eur J Pharmacol 658: 123-131.
129. A receptors. Proc Natl Acad Sci U S A 108: 18150-18155.
130. Simpson C, Itabe H, Reynolds C, King W, Glomset J, (1991). Swiss 3T3 cells preferentially incorporate sn-2-arachidonoyl monoacylglycerol into sn-1-stearoyl-2-arachidonoyl phosphatidylinositol. J Biol Chem 266: 15902-15909.
131. Slanina K, Schweitzer P, (2005). Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus. Neuropharmacology 49: 653-659.
132. Spradley JM, Guindon J, Hohmann AG, (2010). Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol Res 62: 249-258.
133. Staahl C, Olesen AE, Andresen T, Arendt-Nielsen L, Drewes AM, (2009). Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers: an updated review. Br J Clin Pharmacol 68: 322-341.
134. Stella N, Schweitzer P, Piomelli D, (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature 388: 773-778.
135. Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BF, et al,. (2012). Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol 165: 2425-2435.
136. Straiker A, Mackie K, (2009). Cannabinoid signaling in inhibitory autaptic hippocampal neurons. Neuroscience 163: 190-201.
137. Sugiura T, Kondo S, Sugukawa A, Nakane S, Shinoda A, Itoh K, et al,. (1995). 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
138. Sun Y-G, Wu C-S, Lu H-C, Beierlein M, (2011). Target-dependent control of synaptic inhibition by endocannabinoids in the thalamus. J Neurosci 31: 9222-9230.
139. Szabo B, Urbanski M, Bisogno T, Di Marzo V, Mendiguren A, Baer W, et al,. (2006). Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol 577: 263-280.
140. Szabo M, Agostino M, Malone DT, Yuriev E, Capuano B, (2011). The design, synthesis and biological evaluation of novel URB602 analogues as potential monoacylglycerol lipase inhibitors. Bioorg Med Chem Lett 21: 6782-6787.
141. Tarzia G, Antonietti F, Duranti A, Tontini A, Rivara S, Traldi P, et al,. (2007). Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). Ann Chim 97: 887-894.
142. Taschler U, Radner FPW, Heier C, Schreiber R, Schweiger M, Schoiswohl G, et al,. (2011). Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance. J Biol Chem 286: 17467-17477.
143. Tornqvist H, Belfrage P, (1976). Purification and some properties of a monoacylglycerol-hydrolysing enzyme of rat adipose tissue. J Biol Chem 251: 813-819.
144. Tornqvist H, Krabisch L, Belfrage P, (1974). Simple assay for monoacylglycerol hydrolase activity of rat adipose tissue. J Lipid Res 15: 291-294.
145. Vandevoorde S, Saha B, Mahadevan A, Razdan RK, Pertwee RG, Martin BR, et al,. (2005). Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun 337: 104-109.
146. Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ, (2007). Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150: 186-191.
147. Velasco G, Galve-Roperh I, Sánchez C, Blázquez C, Guzmán M, (2004). Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 47: 315-323.
148. Weis F, Beiras-Fernandez A, Hauer D, Hornuss C, Sodian R, Kreth S, et al,. (2010). Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery. Br J Anaesth 105: 139-144.
149. Wilson R, Nicoll R, (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410: 588-592.
150. Woolf CJ, (2010). Overcoming obstacles to developing new analgesics. Nat Med 16: 1241-1247.
151. Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP-V, et al,. (2008a). Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem 103: 234-244.
152. Yang H, Zhang J, Andreasson K, Chen C, (2008b). COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Mol Cell Neurosci 37: 682-695.
153. Yazulla S, (2008). Endocannabinoids in the retina: from marijuana to neuroprotection. Prog Retin Eye Res 27: 501-526.
154. Ye L, Zhang B, Seviour EG, Tao K, -, Liu X, -, Ling Y, et al,. (2011). Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett 307: 6-17.
155. Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D, et al,. (2011). Postsynaptic diacylglycerol lipase α mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex. J Physiol 589: 4857-4884.
156. Zhong P, Pan B, Gao X, -, Blankman JL, Cravatt BF, Liu QS, (2011). Genetic deletion of monoacylglycerol lipase alters endocannabinoid-mediated retrograde synaptic depression in the cerebellum. J Physiol 589: 4847-4855.